Point72 Asset Management’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.21M | Sell |
56,868
-796,511
| -93% | -$51.9M | ﹤0.01% | 1998 |
|
|
2025
Q4 | $68.4M | Buy |
853,379
+810,328
| +1,882% | +$54.4M | 0.08% | 293 |
|
|
2025
Q3 | $2.1M | Sell |
43,051
-395,273
| -90% | -$24.5M | ﹤0.01% | 1425 |
|
|
2025
Q2 | $32.7M | Buy |
438,324
+17,394
| +4% | +$1.15M | 0.06% | 344 |
|
|
2025
Q1 | $26.8M | Buy |
+420,930
| New | +$28.6M | 0.06% | 369 |
|
|
2024
Q3 | – | Sell |
-219,024
| Closed | -$18.1M | – | 2133 |
|
|
2024
Q2 | $18.1M | Buy |
219,024
+140,324
| +178% | +$12.3M | 0.05% | 426 |
|
|
2024
Q1 | $6.72M | Sell |
78,700
-7,383
| -9% | -$579K | 0.02% | 873 |
|
|
2023
Q4 | $7.36M | Buy |
+86,083
| New | +$7.44M | 0.02% | 787 |
|
|
2023
Q2 | – | Sell |
-29,700
| Closed | -$2.46M | – | 2419 |
|
|
2023
Q1 | $2.46M | Sell |
29,700
-344,146
| -92% | -$27.9M | 0.01% | 938 |
|
|
2022
Q4 | $29.4M | Sell |
373,846
-183,693
| -33% | -$14.8M | 0.1% | 249 |
|
|
2022
Q3 | $41.3M | Buy |
557,539
+148,642
| +36% | +$10.7M | 0.16% | 165 |
|
|
2022
Q2 | $26.7M | Buy |
+408,897
| New | +$24.2M | 0.11% | 246 |
|
|
2021
Q4 | – | Sell |
-266,100
| Closed | -$18.8M | – | 1173 |
|
|
2021
Q3 | $18.8M | Buy |
266,100
+175,500
| +194% | +$11.1M | 0.08% | 325 |
|
|
2021
Q2 | $6.04M | Sell |
90,600
-99,100
| -52% | -$7.01M | 0.03% | 573 |
|
|
2021
Q1 | $21.1M | Sell |
189,700
-90,732
| -32% | -$11.2M | 0.1% | 250 |
|
|
2020
Q4 | $33.3M | Sell |
280,432
-1,386,137
| -83% | -$149M | 0.16% | 176 |
|
|
2020
Q3 | $145M | Buy |
1,666,569
+849,744
| +104% | +$74.3M | 0.74% | 15 |
|
|
2020
Q2 | $73.2M | Buy |
816,825
+361,442
| +79% | +$36.5M | 0.48% | 46 |
|
|
2020
Q1 | $45.4M | Buy |
+455,383
| New | +$49.4M | 0.37% | 64 |
|
|
2019
Q3 | – | Sell |
-339,961
| Closed | -$40.9M | – | 1256 |
|
|
2019
Q2 | $40.9M | Sell |
339,961
-519,449
| -60% | -$51.1M | 0.21% | 121 |
|
|
2019
Q1 | $75.2M | Buy |
859,410
+55,648
| +7% | +$5.06M | 0.34% | 68 |
|
|
2018
Q4 | $80.4M | Buy |
803,762
+796,862
| +11,549% | +$83.7M | 0.39% | 67 |
|
|
2018
Q3 | $791K | Buy |
+6,900
| New | +$714K | ﹤0.01% | 867 |
|
|
2018
Q2 | – | Sell |
-61,189
| Closed | -$4.48M | – | 1057 |
|
|
2018
Q1 | $4.48M | Sell |
61,189
-416,011
| -87% | -$28.5M | 0.02% | 598 |
|
|
2017
Q4 | $27.7M | Buy |
+477,200
| New | +$25.1M | 0.12% | 235 |
|
|
2017
Q1 | – | Sell |
-82,058
| Closed | -$3.3M | – | 861 |
|
|
2016
Q4 | $3.3M | Sell |
82,058
-603,742
| -88% | -$22.8M | 0.02% | 495 |
|
|
2016
Q3 | $24.8M | Buy |
+685,800
| New | +$23.5M | 0.17% | 151 |
|
Other funds holding HAE
VPM
VCM
RRAM
Point72 Asset Management's HAE Position: Q1 2026 in Review
Point72 Asset Management reduced its Haemonetics (HAE) stake by 93% in Q1 2026, selling an estimated $51.9M and leaving 56,868 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1998.
Point72 Asset Management first reported a position in HAE in Q3 2016 and has held it in 27 quarters since. The position peaked at $145M in Q3 2020. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Point72 Asset Management held 56,868 shares of Haemonetics worth $3.21M as of Q1 2026.
- Point72 Asset Management sold 796,511 Haemonetics shares in Q1 2026, an estimated $51.9M.
- Haemonetics made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1998 holding.
- Point72 Asset Management first reported a position in Haemonetics in Q3 2016 and has held it in 27 quarters since.
- Point72 Asset Management's Haemonetics position peaked at $145M in Q3 2020.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.